孕烷X受体配体结合结构域蛋白晶体的X线衍射结构解析
|
摘要
目的:利用X线衍射技术解析孕烷X受体(PXR)配体结合结构域(LBD)蛋白晶体的3维结构。方法:对PXR蛋白LBD(130～434氨基酸残基)序列进行密码子优化并化学合成后克隆至pRSFDuet-1表达载体,再将载体导入大肠杆菌BL21(DE3),对PXR-LBD蛋白进行原核表达与分离纯化;采用晶体筛选试剂盒筛选蛋白结晶条件,采用悬滴法获得目标蛋白的晶体;对获得的蛋白晶体进行X线晶体衍射检测,并收集相关数据建立PXR-LBD的三维结构。结果:获得了PXR-LBD的高质量晶体并利用X线衍射解析了该蛋白质晶体的结构数据,使用Phenix.refine软件和COOT软件等对结构进行修正,最终获得了高分辨率的3维结构数据。结论:完成了孕烷X受体配体结合结构域蛋白晶体的X线衍射结构解析,为研究和开发PXR相关药物奠定了基础。
Objective: To obtain the three dimension structure of ligand binding domain(LBD) of pregnane X receptor(PXR) via protein crystals X-ray diffraction methods. Methods: The gene sequence of PXR-LBD(130～434 amino acid residues) was optimized and synthesized, and cloned into vector pRSFDuet-1. Next, the vector was transfected into E.coli BL21(DE3) to express PXR-LBD protein, and then the protein was isolated and purified.Protein crystallization conditions were screened by a crystal screening kit. Crystals of the target protein were obtained by drop method and subjected to X-ray crystal diffraction detection, and related data were collected to establish a three-dimensional structure of PXR-LBD. Results: The high-quality crystal of PXR-LBD was obtained.The high-resolution 3-dimensional structural data were acquired through X-ray diffraction analysis and Phenix.refine software and COOT software modification. Conclusion: The X-ray diffraction structure analysis of the PXRLBD protein crystals was successfully carried out, which laid a solid foundation for the research and development of PXR-related drugs.
Objective: To obtain the three dimension structure of ligand binding domain(LBD) of pregnane X receptor(PXR) via protein crystals X-ray diffraction methods. Methods: The gene sequence of PXR-LBD(130～434 amino acid residues) was optimized and synthesized, and cloned into vector pRSFDuet-1. Next, the vector was transfected into E.coli BL21(DE3) to express PXR-LBD protein, and then the protein was isolated and purified.Protein crystallization conditions were screened by a crystal screening kit. Crystals of the target protein were obtained by drop method and subjected to X-ray crystal diffraction detection, and related data were collected to establish a three-dimensional structure of PXR-LBD. Results: The high-quality crystal of PXR-LBD was obtained.The high-resolution 3-dimensional structural data were acquired through X-ray diffraction analysis and Phenix.refine software and COOT software modification. Conclusion: The X-ray diffraction structure analysis of the PXRLBD protein crystals was successfully carried out, which laid a solid foundation for the research and development of PXR-related drugs.
引文
[1]Polaris Observatory Collaborators.Global prevalence,treatment,and prevention of hepatitis B virus infection in 2016:a modelling study[J].Lancet Gastroenterol Hepatol,2018,3(6):383-403.
[2]Forner A,Reig M,Bruix J.Hepatocellular carcinoma[J].Lancet,2018,391(10127):1301-1314.
[3]Zhu Y J,Zheng B,Wang H Y,et al.New knowledge of the mechanisms of sorafenib resistance in liver cancer[J].Acta Pharmacol Sin,2017,38(5):614-622.
[4]Reig M,Bruix J.Lenvatinib:can a non-inferiority trial change clinical practice[J]?Lancet,2018,391(10126):1123-1124.
[5]Mackowiak B,Hodge J,Stern S,et al.The roles of xenobiotic receptors:beyond chemical disposition[J].Drug Metab Dispos,2018,46(9):1361-1371.
[6]Zhang F,Feng F,Yang P,et al.Four-and-a-halfLIM protein 1 down-regulates estrogen receptorαactivity through repression of AKT phosphorylation in human breast cancer cell[J].Int J Biochem Cell Biol,2012,44(2):320-326.
[7]Shao Z,Li Y,Dai W,et al.ETS-1 induces sorafenibresistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR[J].Pharmacol Res,2018,135:188-200.
[8]Feng F,Jiang Q,Cao S,et al.Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma[J].Biochim Biophys Acta Gen Subj,2018,1862(4):1017-1030.
[9]Wallace B D,Betts L,Talmage G,et al.Structural and functional analysis of the human nuclear xenobiotic receptor PXR in complex with RXRα[J].J Mol Biol,2013,425(14):2561-2577.
[2]Forner A,Reig M,Bruix J.Hepatocellular carcinoma[J].Lancet,2018,391(10127):1301-1314.
[3]Zhu Y J,Zheng B,Wang H Y,et al.New knowledge of the mechanisms of sorafenib resistance in liver cancer[J].Acta Pharmacol Sin,2017,38(5):614-622.
[4]Reig M,Bruix J.Lenvatinib:can a non-inferiority trial change clinical practice[J]?Lancet,2018,391(10126):1123-1124.
[5]Mackowiak B,Hodge J,Stern S,et al.The roles of xenobiotic receptors:beyond chemical disposition[J].Drug Metab Dispos,2018,46(9):1361-1371.
[6]Zhang F,Feng F,Yang P,et al.Four-and-a-halfLIM protein 1 down-regulates estrogen receptorαactivity through repression of AKT phosphorylation in human breast cancer cell[J].Int J Biochem Cell Biol,2012,44(2):320-326.
[7]Shao Z,Li Y,Dai W,et al.ETS-1 induces sorafenibresistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR[J].Pharmacol Res,2018,135:188-200.
[8]Feng F,Jiang Q,Cao S,et al.Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma[J].Biochim Biophys Acta Gen Subj,2018,1862(4):1017-1030.
[9]Wallace B D,Betts L,Talmage G,et al.Structural and functional analysis of the human nuclear xenobiotic receptor PXR in complex with RXRα[J].J Mol Biol,2013,425(14):2561-2577.